body schreef op 9 augustus 2016 12:24:
Uit het persbericht van Valeant vandaag:
We have taken steps to streamline our portfolio in the second quarter. We have sold, or agreed to sell, the brodalumab EU rights, Synergetics USA OEM business, and Ruconest® for a total combined upfront payment of $181 million and additional consideration up to $329 million for achieving specific approval and sales milestones.
Specific to Ruconest, today the Company entered into a definitive agreement to divest all North American commercialization rights to Ruconest (recombinant human C1 esterase inhibitor) to Pharming Group N.V. ("Pharming"). Under the terms of the agreement, Pharming will pay Valeant aggregate consideration of up to $125 million, including an upfront fee of $60 million payable upon closing and certain sales-based milestone payments of up to $65 million. The transaction is subject to customary closing conditions, in addition to Pharming obtaining certain financing. Ruconest was classified as held for sale as of June 30, 2016 and an impairment loss of $199 million was recorded in the second quarter of 2016.
Dus GEEN 'milestone inkomsten voor Pharming maar WEL afkoopkosten van een kleine 500KK...: 'we' worden 'gewoon' weer een dik aantal jaren+ terug gezet als aandeelhouders....; WEL een lichtpunt aan het einde van de tunnel, dat dan weer wel...
Ben benieuwd 'HOE' de markt dit op gaat pakken, lijkt wel of iedereen aan het lunchen is...